参考文献/References:
[1] Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004[J]. CA Cancer J Clin, 2004, 54(1):8-29.
[2] Yanagawa T, Watanabe H, Inoue T, et al. Carbonll-eholine positron emission tomography in musculoskeletal tumors:comparison with fluorine-18 fluorodeoxyglucose positron emission tomography[J]. J Comput Assist Tomogr, 2003, 27(2):175-182.
[3] Zhang H, Tian M, Riuchi N, et al. 11C-choline PET for the detection of bone and soft tissue tummours in comparison with FDG PET[J]. Nucl Med Commun, 2003, 24(3):273-279.
[4] 郭喆,张锦明.11C-胆碱在PET肿瘤显像中的应用[J].同位素,2005,18(3):178-182.
[5] De Jong IJ, Pruim J, Elsinga PH, et al. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET[J]. J Nucl Med, 2003, 44(3):331-335.
[6] Hara T, Kosaka N. Kishi H. PET imaging of prostate cancer using carbon-11-choline[J]. J Nucl Med, 1998, 39(6):990-995.
[7] Kotzerke J, Prang J, Neumaier B. et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma[J]. Eur J Nucl Med, 2000, 27(9):1415-1419.
[8] Picchio M. Messa C, Landoni C, et al. Value of[11C] cholinepositron emission tomography for re-staging prostate:a comparison with[18F] fluorodexyglucose-positron emission tomography[J]. J Urol, 2003, 169(4):1337-1340.
[9] Price D, Coleman R, Liao R, et al. Comparison of[18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer[J]. J Urol, 2002, 168(1):273-280.
[10] Kotzerke J, Volkmer BG, Glatting G, et al. Intraindividual comparison of[11C] acetate and[11C] choline PET for detection of metastases of prostate cancer[J]. Nuklearmedizin, 2003, 42(1):25-30.
[11] Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-llacetate positron emission tomography can detect local recurrence of prostate cancer[J].Eur J Nucl Med Mol Imaging, 2002, 29(10):1380-1384.
[12] Tóth G, Lengyel Z, Balkay L, et al. Detection of prostate cancer with 11C-methionine positron emission tomography[J]. J Urol, 2005, 173(1):66-69.
[13] Nañez R, Macapinlac HA, Yeung HW, et al. Combained 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer[J]. J Nucl Med, 2002, 43(1):46-55.
相似文献/References:
[1]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[2]廖光星,冷志欣,肖国有.前列腺癌骨转移影像诊断方法研究进展[J].国际放射医学核医学杂志,2016,40(6):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
Liao Guangxing,Leng Zhixin,Xiao Guoyou.Progress of imaging in the diagnosis of bone metastases of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):464.[doi:10.3760/cma.j.issn.1673-4114.2016.06.012]
[3]刘辰,杨悦,张雪宁,等.MRI和1997年版Partin表对前列腺癌病理特征预测准确性的对比研究[J].国际放射医学核医学杂志,2015,39(2):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
Liu Chen,Yang Yue,Zhang Xuening,et al.Accuracy of MRI and 1997 edition of Partin tables in predicting the pathological features of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):124.[doi:10.3760/cma.j.issn.1673-4114.2015.02.005]
[4]桂继琮,刘兴党.镭-223氯化物治疗去势抵抗性前列腺癌骨转移的研究进展[J].国际放射医学核医学杂志,2015,39(3):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
Gui Jicong,Liu Xingdang.Development in the study of radium-223 chloride for treating castration-resistant prostate carcinoma with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):268.[doi:10.3760/cma.j.issn.1673-4114.2015.03.018]
[5]张晖,段清,卓娜,等.经直肠超声引导下“6+X”点法前列腺穿刺活检诊断前列腺癌的临床价值分析[J].国际放射医学核医学杂志,2015,39(4):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
Zhang Hui,Duan Qing,Zhuo Na,et al.Meta-analysis of the diagnostic value of transrectal ultrasound-guided “6+X” points biopsy in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(1):308.[doi:10.3760/cma.j.issn.1673-4114.2015.04.008]
[6]张龙敏,刘爱连.前列腺癌MRI诊断技术研究进展[J].国际放射医学核医学杂志,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
Zhang Longmin,Liu Ailian.Advances in MRI diagnosis of prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):53.[doi:10.3760/cma.j.issn 1673-4114.2014.01.011]
[7]刘辰,杨悦,张雪宁,等.CT/MRI图像融合在前列腺癌IMRT中的应用进展[J].国际放射医学核医学杂志,2014,38(4):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
Liu Chen,Yang Yue,Zhang Xuening,et al.CT/MRI image fusion in intensity modulated radiation therapy for prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(1):247.[doi:10.3760/cma.j.issn.1673-4114.2014.04.010]
[8]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(1):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[9]韦赐秋.中老年男性血清前列腺特异性抗原测定的临床价值[J].国际放射医学核医学杂志,2010,34(5):302.[doi:10.3760/cma.j.issn.1673-4114.2010.05.014]
[10]徐慧琴,薛杨央,赵学峰,等.18F-FDG PET-CT诊断前列腺癌复发与转移的价值[J].国际放射医学核医学杂志,2011,35(2):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]
XU Hui-qin,XUE Yang-yang,ZHAO Xue-feng,et al.Value of 18F-FDG PET-CT in diagnoss of prostate cancer recurrence and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(1):81.[doi:10.3760/cma.j.issn.1673-4114.2011.02.004]